Targeting chemokines in lymphoma

Targeting chemokines in lymphoma

VJHemOnc

2 years
215 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Francine Foss, MD, from the Yale University School of Medicine, New Haven, CT, discusses targeting chemokines at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada. Chemokines are a group of molecules that are expressed in the microenvironment of T- and B-cell malignancies. The anti-CCR4 antibody has been developed, and there is now research into whether there is a role for other chemokine therapy in lymphoma. There is also the possibility for targeting specific chemokines that affect the growth of the tumor cell to be targeted, as well as those associated with migration and metastasis.
Up Next Autoplay
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
0 Views
cancergrace 1 day
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
0 Views
Cancer-News 2 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 2 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 2 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 2 days
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
Category: Brain Cancer
4 Views
Massachusetts General Hospital 2 days